Steffen Johnson Speaks at Third Annual Pharmaceutical Labeling Summit

Winston & Strawn partner Steffen Johnson, based in the Washington, D.C. office, moderated a panel at the Third Annual Pharmaceutical Labeling Summit, held October 16-17, 2012 in Washington, D.C. The summit included drug and biologic industry executives, FDA officials, industry attorneys and thought leaders and covered the common issues and the future of pharmaceutical labeling and revision.

Mr. Johnson moderated the panel, "PLIVA v. Mensing Redux? What Does the First Circuit Court of Appeals Decision in Barlett v. Mutual Mean for Generic Preemption?" This panel discussed and debated the intricacies of Bartlett v. Mutual and how it related to PLIVA v. Mensing, as Mutual Pharmaceutical is calling on the Supreme Court to reverse an appeals court decision that upheld a $21 million jury award. Mr. Johnson recently filed a brief in the Bartlett case on behalf of six major generic pharmaceutical companies.

Mr. Johnson, a member of Winston & Strawn's nationwide appellate and critical motions practice, has extensive experience in complex appellate, commercial, and constitutional litigation. He has personally argued in the Supreme Court of the United States, and he has served as counsel in nearly 50 cases before the Court, including several cases in which he has represented parties at the merits stage. For example, he recently served as counsel of record for the prevailing petitioners in Caraco Pharmaceuticals v. Novo Nordisk A/S, 132 S. Ct. 1670 (2012), the Supreme Court's first-ever case involving the drug competition provisions of the Hatch-Waxman Act. He has also briefed and argued numerous cases in the lower federal and state appellate courts, including several federal circuits.